CAR T cells produced in vivo to treat cardiac injury
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Making CAR T cells in vivo: Cardiac fibrosis is the stiffening and scarring of heart tissue and can be fatal. Rurik et al . designed an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the fibrotic cells in the heart (see the Perspective by Gao and Chen). By injecting CD5-targeted lipid nanoparticles containing the messenger RNA (mRNA) instructions needed to reprogram T lymphocytes, the researchers were able to generate therapeutic CAR T cells entirely inside the body. Analysis of a mouse model of heart disease revealed that the approach was successful in reducing fibrosis and restoring cardiac function. The ability to produce CAR T cells in vivo using modified mRNA may have a number of therapeutic applications. —PNK
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We used an Ang II/PE infusion model to study cardiac fibrosis which has inherent limitations3,4,7,39”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent advances in CAR T-cell technology have provided a much needed breakthrough and indicated that selectively removing activated cardiac fibroblasts that express fibroblast activator protein (FAP) is sufficient to ameliorate fibrosis without impacting the structural integrity of the heart in preclinical mouse models 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies have implicated a potential pathogenic role for FAP+ fibroblasts in mouse models of cardiac remodelling3,4.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“LNPs and CAR-T cells have been combined for antifibrotic therapy in experimental heart fibrosis by administering LNPs that reprogram host lymphocytes into CAR-T cells in order to target cardiac myofibroblasts that express fibroblast activation peptide alpha (FAP) (129).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies have utilized chimeric antigen receptor (CAR) T cells to target FAP + fibroblasts in a mouse model of cardiac injury and shown improved cardiac function and diminished fibrosis 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citationKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citationFibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Self-citationFibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94753 · Cited by 905
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Cited by
Items 401–500 of 1,001
A cardioimmunologist’s toolkit: genetic tools to dissect immune cells in cardiac disease
Wong, A., Hamidzada, H., & Epelman, S. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00701-0 · Cited by 32
Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor
Zuo, Y.-H., Zhao, X., & Fan, X. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106454 · Cited by 28
Gene editing innovations and their applications in cardiomyopathy research
Kyriakopoulou, E., Monnikhof, T., & van Rooij, E. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.050088 · Cited by 29
Zhang, Y., Yang, J., Zhang, T., & Gu, H. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1211687 · Cited by 30
Lee, G., Choi, Y., Hong, J., Kim, J., Chae, J., Ahn, S., Ha, H.-J., Jeong, E., Lee, H., & Choi, J. H. (2024) · BioChip Journal · doi:10.1007/s13206-024-00147-1 · Cited by 27
Strategies for enhanced gene delivery to the central nervous system
Gao, Z. (2024) · Nanoscale Advances · doi:10.1039/d3na01125a · Cited by 29
Monitoring mRNA vaccine antigen expression in vivo using PET/CT
Blizard, G. S., Dwivedi, G., Pan, Y., Hou, C., Etersque, J. M., Said, H., Chevrier, A., Lavertu, M., Ni, H., Davis, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57446-w · Cited by 29
Self-citationYong, H., Tian, Y., Li, Z., Wang, C., Zhou, D., Liu, J., Huang, X., & Li, J. (2025) · Advanced Materials · doi:10.1002/adma.202414991 · Cited by 26
Shuvaev, V. V., Tam, Y. K., Lee, B. W., Myerson, J. W., Herbst, D. A., Kiseleva, R. Y., Glassman, P. M., Parhiz, H., Alameh, M., Pardi, N., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409266122 · Cited by 27
Self-citationLipid nanoparticle-mediated targeted mRNA delivery and its application in cancer therapy
Sui, Y., Hou, X., Zhang, J., Hong, X., Wang, H., Xiao, Y., & Zeng, X. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01556a · Cited by 28
Smart CAR-T Nanosymbionts: archetypes and proto-models
Baena, J. C., Victoria, J. S., Toro-Pedroza, A., Aragón, C. C., Ortiz‐Guzman, J., García-Robledo, J. E., Torres, D., Ríos-Serna, L. J., Albornóz, L. L., Rosales, J. D., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1635159 · Cited by 28
Cardiac fibrosis: from mechanisms and models to medicines
Liu, W., Wu, X., Zeng, W., Chandy, M., & Wu, J. C. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.07.016 · Cited by 27
CAR T Cell Therapy for Rheumatoid Arthritis
Freeley, M. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09113-7 · Cited by 25
Roads and detours for CAR T cell therapy in autoimmune diseases
Avouac, J., Barzel, A., Caiati, D., Davis, R. S., Gottschalk, S. M., Grieshaber‐Bouyer, R., Mao, X., Prak, E. T. L., Radic, M. Z., Scherlinger, M., et al. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01349-4 · Cited by 28
Gene therapy for heart failure and cardiomyopathies
Argirò, A., Ding, J., & ADLER, E. D. (2023) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2023.06.009 · Cited by 35
Surface modification of lipid nanoparticles for gene therapy
Tafech, B., Mohabatpour, F., & Hedtrich, S. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3642 · Cited by 25
In Situ Reprogramming of Immune Cells Using Synthetic Nanomaterials
Nie, S., Qin, Y., Ou, L., Chen, X. S., & Li, L. (2024) · Advanced Materials · doi:10.1002/adma.202310168 · Cited by 25
Self-citationLipid nanoparticles deliver mRNA to the blood–brain barrier
Kuzminich, Y., Shakked, A., Calkins, R., Rudden, S., Jones, C., Doan, J., Jang, B., Echeverri, E. S., Zenhausern, R., Lian, L., et al. (2024) · Nano Research · doi:10.1007/s12274-024-6827-7 · Cited by 26
Liu, Y., Zhou, M., Xu, M., Wang, X., Zhang, Y., Deng, Y., Zhang, Z., Jiang, J., Zhou, X., & Li, C. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.045 · Cited by 25
mRNA medicine: Recent progresses in chemical modification, design, and engineering
Hou, X., Shi, J., & Xiao, Y. (2024) · Nano Research · doi:10.1007/s12274-024-6978-6 · Cited by 28
Cardiac involvement in systemic sclerosis: A critical review of knowledge gaps and opportunities
Jones, X. M., Bottini, N., Boin, F., & Marbán, E. (2025) · Journal of Scleroderma and Related Disorders · doi:10.1177/23971983241313096 · Cited by 28
Chen, Q., Yu, T., Gong, J., & Shan, H. (2025) · Molecules · doi:10.3390/molecules30040962 · Cited by 32
Using RNA therapeutics to promote healthy aging
Chen, S., Chen, Q., You, X., Zhou, Z., Kong, N., Ambrosio, F., Cao, Y., Abdi, R., & Tao, W. (2025) · Nature Aging · doi:10.1038/s43587-025-00895-1 · Cited by 25
Cheng, J., Gao, R., Lyu, Y., Xiong, Z. L., Yang, K., Zhao, X., Huang, X., Xu, L., Guo, L., Wang, W., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c05068 · Cited by 25
Wallon, L., Khan, I., Teng, K. W., Koide, A., Zuberi, M., Li, J., Ketavarapu, G., Traaseth, N. J., O’Bryan, J. P., & Koide, S. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204481119 · Cited by 26
A Unified Model of Age-Related Cardiovascular Disease
Fossel, M., Bean, J., Khera, N., & Kolonin, M. G. (2022) · Biology · doi:10.3390/biology11121768 · Cited by 26
Nian, W., Huang, Z., & Fu, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1097295 · Cited by 25
Liang, T., Song, Y., Gu, L., Wang, Y., & Ma, W. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s418837 · Cited by 26
The therapeutic potential of immunoengineering for systemic autoimmunity
McBride, D. A., Jones, R. M., Bottini, N., & Shah, N. J. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01084-x · Cited by 24
Wang, Y., Yang, M., Zhang, B.-Y., Zhao, G., Zhou, S., Lu, Z.-D., Xu, C., & Wang, J. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100011 · Cited by 24
Yadav, S., Anbalagan, M., Khatun, S., Prabhakaran, D., Matsunaga, Y., Manges, J., McLachlan, J. B., Lasky, J. A., Kolls, J. K., & Thannickal, V. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci181775 · Cited by 26
In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines
Meng, S., Hara, T., Miura, Y., Arao, Y., Saito, Y., Inoue, K., Hirotsu, T., Vecchione, A. M., Satoh, T., & Ishii, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073119 · Cited by 26
Lei, S., Li, J., Zhu, M., Zhou, W., Fu, X., Wu, S., Chen, X., Zhang, J., Duan, X., Wang, W., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c18153 · Cited by 25
Gong, Y., Fei, P., Zhang, Y., Xu, Y., & Wei, J. (2025) · Advanced Science · doi:10.1002/advs.202501095 · Cited by 29
Song, M., Liu, B., Wang, H., & Sun, W. (2025) · MedComm · doi:10.1002/mco2.70269 · Cited by 31
Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives
Shang, D., Zhou, Z., Shi, R., Wang, Z., Zhang, P., Fu, P., Li, H., Cheng, G., Qin, H., Xie, Z., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02476-7 · Cited by 28
Niederkofler, S., Parkkila, P., Aliakbarinodehi, N., Sasanian, N., Emilsson, G., Ulkoski, D., Ferreira, C. J. O., Galenkamp, N. S., Silva, B. F. B., Lundberg, D., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c17052 · Cited by 26
Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer
Ferrer, G., Álvarez‐Errico, D., & Esteller, M. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac088 · Cited by 24
Parlani, M., Bedell, M. L., Mikos, A. G., Friedl, P., & Dondossola, E. (2022) · Science Advances · doi:10.1126/sciadv.add0014 · Cited by 25
Huang, L., Zhao, F., He, M., Fang, Y., Ma, X., Lu, S., Li, E., Xiao, H. Q., Zhu, H., Wang, X., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.002 · Cited by 24
Immune in myocardial ischemia/reperfusion injury: potential mechanisms and therapeutic strategies
Xuan, X., Fan, J., Zhang, J., Ren, M., & Feng, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1558484 · Cited by 24
mRNA delivery systems 2.0: Engineering extrahepatic delivery for non-vaccine therapeutics
Dalabehera, M., Ghosh, A., Mohanty, S., Chellappan, D. K., Chaudhari, S., Ale, Y., Poonia, N., Subudhi, R. N., Khanna, M., & Lim, H. G. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102584 · Cited by 27
Li, B., Wang, J., Ye, P., Liu, C., Ming, Y., Yang, B., He, D., Lai, W., Guo, L., Zhao, M., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c14271 · Cited by 25
Ferrer‐Curriu, G., Soler‐Botija, C., Charvátová, S., Motais, B., Roura, S., Gálvez‐Montón, C., Tortajada, M., Egea, O. I., Emdin, M., Lupón, J., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114061 · Cited by 22
Automating CAR‐T Transfection with Micro and Nano‐Technologies
Hu, T., Kumar, A. R. K., Luo, Y., & Tay, A. K. P. (2023) · Small Methods · doi:10.1002/smtd.202301300 · Cited by 22
Zhu, L., Man, C., Harrison, R. E. S., Wu, Z., Limsakul, P., Qin, P., Hashimoto, M., Mamaril, A. P., Xu, H., Liu, L., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c01597 · Cited by 22
Harnessing nanoengineered CAR-T cell strategies to advance solid tumor immunotherapy
Wang, X., Fan, R., Mu, M., Zhou, L., Zou, B., Tong, A., & Guo, G. F. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.11.010 · Cited by 28
Leveraging biomaterials for enhancing T cell immunotherapy
Liao, Z., Zhang, W., Zheng, H., Wang, Y., Yu, J., Li, H., & Gu, Z. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.023 · Cited by 22
Nonviral targeted mRNA delivery: principles, progresses, and challenges
He, X., Li, G., Huang, L., Shi, H., Zhong, S., Zhao, S., Jiao, X., Xin, J., Yin, X., Liu, S., et al. (2025) · MedComm · doi:10.1002/mco2.70035 · Cited by 28
Liu, C., Jiang, Y., Xue, W., Liu, J., Wang, Z., Luo, J., & Li, X. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c14203 · Cited by 22
Technologies for chimeric antigen receptor transgene delivery
Xiao, Y., Wu, B., Zhou, Q., Wu, F., Li, N., Xu, C., & Han, X. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.05.011 · Cited by 23
Formulation methods for peptide-modified lipid nanoparticles
Miyasaki, K. F., Han, S. W., Carton, O., Kandell, R. M., Gunn, J., & Kwon, E. J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114030 · Cited by 22
Advances and obstacles of T cell-based immunotherapy in gynecological malignancies
Zhao, X., Ran, J., Li, S., & Chen, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02411-w · Cited by 25
Cardiac fibrosis in oncologic therapies
Packard, R. R. S. (2022) · Current Opinion in Physiology · doi:10.1016/j.cophys.2022.100575 · Cited by 23
Duan, Q., Hu, T., Zhu, Q., Jin, X., Chi, F., & Chen, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.974433 · Cited by 21
Ma, T., Chen, X., & Wang, M. (2023) · ChemBioChem · doi:10.1002/cbic.202200801 · Cited by 24
Targeted adenovirus-mediated transduction of human T cells in vitro and in vivo
Freitag, P. C., Kaulfuß, M., Flühler, L., Mietz, J., Weiss, F., Brücher, D., Kolibius, J., Hartmann, K. P., Smith, S. N., Münz, C., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.02.012 · Cited by 21
mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic
Xu, Z., & Fisher, D. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155728 · Cited by 29
Drzeniek, N. M., Kahwaji, N., Picht, S., Dimitriou, I. M., Schlickeiser, S., Moradian, H., Geissler, S., Schmueck‐Henneresse, M., Gossen, M., & Volk, H. (2024) · Advanced Science · doi:10.1002/advs.202308447 · Cited by 18
Recent advances in targeted therapy for inflammatory vascular diseases
Zhao, K., Zeng, Z., He, Y., Zhao, R., Niu, J., Sun, H., Li, S., Dong, J., Jing, Z., & Zhou, J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.063 · Cited by 24
Spokeviciute, B., Kholia, S., & Brizzi, M. F. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107352 · Cited by 23
Advances in the study of LNPs for mRNA delivery and clinical applications
Wang, B., Shen, B., Xiang, W., & Shen, H. (2024) · Virus Genes · doi:10.1007/s11262-024-02102-6 · Cited by 22
Engineering CAR‐T Therapeutics for Enhanced Solid Tumor Targeting
Zhu, D., Kim, W., Lee, H., Bao, X., & Kim, P. (2025) · Advanced Materials · doi:10.1002/adma.202414882 · Cited by 32
Mammalian Sulfatases: Biochemistry, Disease Manifestation, and Therapy
Mashima, R., & Nakanishi, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158153 · Cited by 21
Xiong, H., & Guo, J. (2025) · Pharmaceuticals · doi:10.3390/ph18040507 · Cited by 24
Miao, D., Song, Y., Fan, Z., Ji, C., Hua, J., Zhao, X., Zhang, J., Huang, C., & Xiong, R. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2025.138696 · Cited by 20
Lanzer, J. D., Flores, R. O. R., Liñares-Blanco, J., Steier, M., Rangrez, A. Y., Frey, N., & Sáez-Rodríguez, J. (2025) · Nature Communications · doi:10.1038/s41467-025-62219-6 · Cited by 24
Lemgart, V. T., Sawyer, A. J., Kuhlman, W. A., Griset, A. P., Ali, M. M., Caron, A., Shah, D., Le, T. T., Strauss, L., Jiao, J., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.020 · Cited by 25
Moita, M. R., Silva, M. M., Diniz, C., Serra, M., Hoet, R., Barbas, A., & Simão, D. F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1015473 · Cited by 23
Yu, X., Xu, T., Shi, H., Hong, J., Jin, X., Cao, L., Wang, J., Lin, Y., Pan, Z., Wang, S., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.142841 · Cited by 20
Rapid Generation of Therapeutic Nanoparticles Using Cell‐Free Expression Systems
Peruzzi, J. A., Vu, T. Q., Gunnels, T. F., & Kamat, N. P. (2023) · Small Methods · doi:10.1002/smtd.202201718 · Cited by 20
In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy
Śledź, M., Wojciechowska, A., Zagożdżon, R., & Kaleta, B. (2023) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-023-00683-y · Cited by 22
Mittra, S., Harding, S. M., & Kaech, S. M. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300049 · Cited by 21
A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy
Lee, I. K., Sharma, N., Noguera-Ortega, E., Liousia, M., Baroja, M. L., Etersque, J. M., Pham, J. M., Sarkar, S., Carreno, B. M., Linette, G. P., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.020 · Cited by 22
Self-citationGu, J., Xu, Z., Liu, Q., Tang, S., Zhang, W., Xie, S., Chen, X., Chen, J., Yong, K., Yang, C., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302409 · Cited by 21
Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid‐Based Nanoparticles
Fernandes, S., Cassani, M., Cavalieri, F., Forte, G., & Caruso, F. (2023) · Advanced Science · doi:10.1002/advs.202305769 · Cited by 22
Advances in non-viral mRNA delivery to the spleen
Narasipura, E. A., & Fenton, O. S. (2024) · Biomaterials Science · doi:10.1039/d4bm00038b · Cited by 21
Emerging mRNA Technology for Liver Disease Therapy
Wang, J., Fang, Y., Luo, Z., Wang, J., & Zhao, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c02987 · Cited by 21
Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment
Kang, X., Mita, N., Zhou, L., Wu, S., Yue, Z., Babu, R. J., & Chen, P. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091228 · Cited by 22
Gu, Z., Liu, T., Rao, W., Li, D., Zhang, Q., Dai, J., Huang, L., Wang, J., & Hou, X. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202412335 · Cited by 20
Hernández-López, A., Olaya‐Vargas, A., Bustamante‐Ogando, J. C., & Meneses‐Acosta, A. (2025) · Pharmaceuticals · doi:10.3390/ph18020156 · Cited by 22
Effective transcatheter intracoronary delivery of mRNA-lipid nanoparticles targeting the heart
Handa, K., Kawamura, M., Sasai, M., Matsuzaki, T., Harada, A., Fujimura, L., Whitehouse, J., Saito, S., Komukai, S., Kitamura, T., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113623 · Cited by 22
Applications of mRNA Delivery in Cancer Immunotherapy
Pan, X., Zhang, Y.-W.-Q., Dai, C., Zhang, J., Zhang, M., & Chen, X. X. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s500520 · Cited by 21
In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy
Huang, Y., Cao, R. Y., Wang, S., Chen, X., Yü, P., & Zhang, Y. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2558403 · Cited by 23
Regulatory T Cell Therapeutics for Neuroinflammatory Disorders
Harkins, A. L., Kopec, A. L., & Keeler, A. M. (2022) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2022045080 · Cited by 19
The grand challenge of discovering new cardiovascular drugs
Hong, C. C. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.1027401 · Cited by 21
mRNA therapy for myocardial infarction: A review of targets and delivery vehicles
Wang, X., Wu, D. H., & Senyo, S. E. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1037051 · Cited by 20
Cardiomyocyte-fibroblast crosstalk in the postnatal heart
Calderon, M. U., Gonzalez, B. A., & Yutzey, K. E. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1163331 · Cited by 22
Guerra, A., Parhiz, H., & Rivella, S. (2023) · Haematologica · doi:10.3324/haematol.2023.283057 · Cited by 21
Self-citationTolerogenic Nano-/Microparticle Vaccines for Immunotherapy
Liu, Q., Chen, G., Liu, X., Tao, L., Fan, Y., & Xia, T. (2024) · ACS Nano · doi:10.1021/acsnano.3c11647 · Cited by 29
Multiscale physics-based in silico modelling of nanocarrier-assisted intravascular drug delivery
Buchete, N., Cicha, I., Dutta, S., & Neofytou, P. (2024) · Frontiers in Drug Delivery · doi:10.3389/fddev.2024.1362660 · Cited by 24
RNA-loaded nanoparticles for the treatment of hematological cancers
Garbayo, E., Moukhtari, S. H. E., Rodríguez‐Nogales, C., Agirre, X., Rodríguez-Madoz, J. R., Rodríguez-Márquez, P., Prósper, F., Couvreur, P., & Blanco‐Prieto, M. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115448 · Cited by 20
Activation of Imprinted Gene PW1 Promotes Cardiac Fibrosis After Ischemic Injury
Kou, S., Lu, Z., Deng, D., Ye, M., Yu, S., Qin, L., Feng, T., Jiang, Z., Meng, J., Lin, C., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.070738 · Cited by 19
Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond
Yang, Z., Ha, B., Wu, Q., Ren, F., Yin, Z., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544532 · Cited by 24
Myocardial-Treg Crosstalk: How to Tame a Wolf
Weiß, E., Ramos, G. C., & Delgobo, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.914033 · Cited by 20
Multiplexed engineering and precision gene editing in cellular immunotherapy
Biederstädt, A., Manzar, G. S., & Daher, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1063303 · Cited by 20
ACLY Promotes Cardiac Fibrosis via the Regulation of DNL and Histone Acetylation
Kuwahara, N., Nagao, M., Shinohara, M., Kaneshiro, K., Emoto, T., Yoshida, T., Fukuda, T., Nishimori, M., Satomi‐Kobayashi, S., Otake, H., et al. (2025) · Hypertension · doi:10.1161/hypertensionaha.124.24088 · Cited by 19
Muto, H., Kubara, K., Hitaoka, S., Osada, Y., & Suzuki, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114055 · Cited by 20
Nanotechnology for CAR T cells and tumour-infiltrating lymphocyte therapies
Lafuente‐Gómez, N., Kang, S. J., & Mooney, D. J. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-02008-w · Cited by 22
Targeted delivery of genome editors in vivo
Ngo, W., Wu, J. L. Y., Wasko, K. M., & Doudna, J. A. (2026) · Nature Biotechnology · doi:10.1038/s41587-025-02945-w · Cited by 22
Metadata
- Authors
- Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., Mui, B. L., Albelda, S. M., Puré, E., June, C. H., Aghajanian, H., Weissman, D., Parhiz, H., & Epstein, J. A.
- Affiliations
- University of Pennsylvania (US)
- Department of Cell and Developmental Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Acuitas Therapeutics (Canada) (CA)
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Corresponding author
- Tombácz, István
- Yadegari, Amir
- Aghajanian, Haig
- Weissman, Drew
- Parhiz, Hamideh
- Epstein, Jonathan A.
- ORCID
- Venue
- Science
- Published
- 2022-01-07
- Volume
- 375
- Issue
- 6576
- Pages
- 91-96
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9983611
- OpenAlex
- W4206716689
- Cited by
- 1,400
- References
- 36
- Citations by year
- 2026: 375 · 2025: 348 · 2024: 312 · 2023: 215 · 2022: 148
- FWCI
- 106.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL134839, R35HL140018)
- National Institute of Allergy and Infectious Diseases (R01AI124429, U19AI142596, P30AI045008)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- chimeric antigen receptor T cells, myocardial fibrosis, heart failure, lipid nanoparticles, mRNA delivery, antifibrotic therapy, trogocytosis, cardiac injury
- MeSH terms
- Receptors, Chimeric Antigen, Trogocytosis, Fibroblast Activation Protein Alpha, Animals, Fibroblasts, Fibrosis, Heart Diseases, Heart Failure, Humans, Liposomes, Male, Membrane Proteins, Mice, Inbred C57BL, Myocardium, Endopeptidases, RNA, Messenger, Spleen, T-Lymphocytes, Immunotherapy, Adoptive, CD5 Antigens, Adoptive Transfer, Mice, Nanoparticles, HEK293 Cells, Cell Engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.